Current Opinion in Molecular Therapeutics is designed to provide an overview of the most important developments across this field of research and saves you from having to hunt through the proliferation of scientific literature.

Throughout the course of a year the journal highlights relevant progress made in gene therapy, vaccines, oligonucleotides, gene delivery systems, vectors, genomics and proteomics.

The division of this vast field into sections, makes it easier to follow the continuous developments from year to year.

February
Molecular, viral and cell-based vaccines for disease prevention and therapy

April
Oligonucleotide, antibody and peptide therapeutics - From design to the clinic

June
Genomics, proteomics and pharmacogenetics - Experimental approaches

August
Gene transfer and cell-based therapies

October
Clinical applications of gene therapy

December
Genomics, proteomics and pharmacogenetics - Therapeutic approaches

Each issue of Current Opinion in Molecular Therapeutics contains the following sections:

Paper and Patent alerts
Commentary on a selection of recently published papers and patents, identified as being of particular interest, is provided.

Web alert
A selection of World Wide Web sites relevant to the contents of Current Opinion in Molecular Therapeutics are included in each issue.

Editorial overview
Short overview at the beginning of each issue to introduce the reviews and to draw the readers attention to any particularly interesting developments.

Reviews
Reviews of recent developments in a specific field. All reviews are peer reviewed.

Drug evaluations
Expert commentary on the scientific and commercial potential of selected drugs in clinical trials are provided in each issue, in the form of drug evaluations. Opinion on the drug's potential, with a personal viewpoint on its therapeutic and economic viability, are included. All drug evaluations are peer reviewed.